TABLE 2. Effectiveness of 2024–2025 COVID-19 vaccination against COVID-19–associated emergency department or urgent care encounters, by age group — VISION, September 2024–January 2025.
| Age group/COVID-19 vaccination dosage pattern | COVID-19 case-patients No. (col %) | COVID-19 control patients No. (col %) | Median interval since last dose for vaccinated, days (IQR) | VE %* (95% CI) |
|---|---|---|---|---|
|
≥18 yrs
| ||||
| No 2024–2025 dose† (Ref) |
9,545 (91) |
108,972 (86) |
998 (539–1,142) |
Ref |
| Received 2024–2025 dose | ||||
| 7–119 days earlier |
914 (9) |
18,112 (14) |
55 (32–80) |
33 (28–38) |
| 7–59 days earlier |
480 (5) |
9,789 (8) |
33 (20–46) |
36 (29–42) |
| 60–119 days earlier |
434 (4) |
8,323 (7) |
82 (71–97) |
30 (22–37) |
|
18–64 yrs
| ||||
| No 2024–2025 dose† (Ref) |
5,860 (96) |
76,792 (93) |
1,042 (751–1,180) |
Ref |
| Received 2024–2025 dose | ||||
| 7–119 days earlier |
253 (4) |
5,953 (7) |
53 (29–77) |
30 (20–39) |
| 7–59 days earlier |
134 (2) |
3,379 (4) |
32 (20–45) |
36 (23–46) |
| 60–119 days earlier |
119 (2) |
2,574 (3) |
81 (70–95) |
21 (5–35) |
|
≥65 yrs
| ||||
| No 2024–2025 dose† (Ref) |
3,685 (85) |
32,180 (73) |
750 (346–1,076) |
Ref |
| Received 2024–2025 dose | ||||
| 7–119 days earlier |
661 (15) |
12,159 (27) |
57 (33–82) |
35 (29–41) |
| 7–59 days earlier |
346 (8) |
6,410 (14) |
34 (21–47) |
36 (28–44) |
| 60–119 days earlier | 315 (7) | 5,749 (13) | 83 (71–97) | 34 (25–42) |
Abbreviations: Ref = referent group; VE = vaccine effectiveness; VISION = Virtual SARS-CoV-2, Influenza, and Other respiratory viruses Network.
* VE was calculated by comparing the odds of 2024–2025 COVID-19 vaccination among case-patients and control patients using the following equation: (1 – adjusted odds ratio) x 100%. Odds ratios were estimated by multivariable logistic regression. The odds ratio was adjusted for age, sex, race and ethnicity, calendar day, and geographic region. † The “no 2024–2025 dose” group included all eligible persons who did not receive a 2024–2025 COVID-19 vaccine dose, regardless of number of previous COVID-19 vaccine doses (if any) received.